文献速递血栓与止血

托珠单抗与秋水仙碱对COVID-19相关凝血病作用迥异:α-防御素的作用

Divergent impacts of tocilizumab and colchicine in COVID-19-associated coagulopathy: the role of alpha-defensins.
PubMed 文献 · Br J Haematol · 2021-10-27

研究基于两项临床试验数据,探讨托珠单抗(TCZ)与秋水仙碱对COVID-19患者D-二聚体水平的不同影响。结果发现TCZ显著升高IL-6、α-防御素(α-Def)和D-二聚体,而秋水仙碱降低α-Def和D-二聚体。体外实验显示IL-6刺激中性粒细胞释放α-Def,TCZ不能抑制此效应,提示TCZ升高的IL-6可能通过α-Def促进血栓形成。

要点

  • TCZ显著升高COVID-19患者IL-6、α-Def和D-二聚体水平。
  • 秋水仙碱可降低COVID-19患者α-Def和D-二聚体水平。
  • IL-6刺激中性粒细胞释放α-Def,TCZ不能抑制该刺激效应。

核心结论

  • TCZ可能通过升高IL-6触发α-Def释放,从而促进COVID-19相关血栓形成并升高D-二聚体。
  • 秋水仙碱降低α-Def和D-二聚体,可能减轻COVID-19相关凝血病。

研究设计与样本

  • 数据来自两项研究者实施的临床试验。
  • 第一项试验中,TCZ以8 mg/kg剂量给予COVID-19 PCR阳性患者。
  • 另进行体外研究探讨IL-6对中性粒细胞释放α-Def的影响。

主要发现

  • TCZ显著增加IL-6、α-防御素(α-Def)和D-二聚体水平。
  • 秋水仙碱降低α-Def和D-二聚体水平。
  • 体外研究表明IL-6刺激人中性粒细胞释放α-Def。
  • 与秋水仙碱不同,TCZ不能抑制IL-6的刺激效应。

关键数值与推荐

  • TCZ给药剂量为8 mg/kg。

临床怎么用

  • 在COVID-19相关凝血病中,需关注TCZ可能升高D-二聚体的风险。
  • 秋水仙碱可能作为降低α-Def和D-二聚体的潜在选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients who are severely affected by coronavirus disease 2019 (COVID-19) may develop a delayed onset 'cytokine storm', which includes an increase in interleukin-6 (IL-6). This may be followed by a pro-thrombotic state and increased D-dimers. It was anticipated that tocilizumab (TCZ), an anti-IL-6 receptor monoclonal antibody, would mitigate inflammation and coagulation in patients with COVID-19. However, clinical trials with TCZ have recorded an increase in D-dimer levels. In contrast to TCZ, colchicine reduced D-dimer levels in patients with COVID-19. To understand how the two anti-inflammatory agents have diverse effects on D-dimer levels, we present data from two clinical trials that we performed. In the first trial, TCZ was administered (8 mg/kg) to patients who had a positive polymerase chain reaction test for COVID-19. In the second trial, colchicine was given (0·5 mg twice a day). We found that TCZ significantly increased IL-6, α-Defensin (α-Def), a pro-thrombotic peptide, and D-dimers. In contrast, treatment with colchicine reduced α-Def and Di-dimer levels. In vitro studies show that IL-6 stimulated the release of α-Def from human neutrophils but in contrast to colchicine, TCZ did not inhibit the stimulatory effect of IL-6; raising the possibility that the increase in IL-6 in patients with COVID-19 treated with TCZ triggers the release of α-Def, which promotes pro-thrombotic events reflected in an increase in D-dimer levels.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Abdeen S, Abu-Fanne R, Bdeir K, et al. Divergent impacts of tocilizumab and colchicine in COVID-19-associated coagulopathy: the role of alpha-defensins. Br J Haematol. 2021. PMID: 34622440. doi:10.1111/bjh.17885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。